Market Overview:
The global interleukin 12 receptor market is expected to grow at a CAGR of xx% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of autoimmune diseases, rising geriatric population, and growing demand for targeted therapies. Based on type, the global interleukin 12 receptor market is segmented into edodekin alfa SR, M-9241, LY-3232094, NMIL-121 and others. Based on application, the global interleukin 12 receptor market is segmented into inpatient and outpatient settings. Geographically, the global interleukin 12 receptor market is segmented into North America (U.S., Canada), Latin America (Mexico), Europe (Germany France Italy Spain U.K.), Asia Pacific (China Japan India South Korea Australia) and Middle East & Africa (Saudi Arabia UAE Qatar South Africa).
Product Definition:
Interleukin 12 receptor is a protein found on the surface of cells. It is used by Interleukin 12 to interact with other cells and signals the body to produce more white blood cells.
Edodekin Alfa SR:
Edodekin Alfa SR (edocressin) is a peptide hormone, which is produced by the stomach and small intestine of humans. Edodekin alfa sr has sequence homology with interleukin-12 receptor alpha chain. Interleukin 12 receptor or simply IL-12R refers to a type of cytokine that binds theIL-12 antibody - also called as Janus kinase 2 (JAK2).
M-9241:
M-9241 is a novel interleukin 12 receptor (IL12R) modulator which enhances the immune response to IL-12. It was developed by Merck KGaA and is currently in phase II clinical trials for approval. The drug has shown promising safety and efficacy data in Phase I study, which has led to an investigation of its potential as a therapeutic vaccine for multiple sclerosis.
Application Insights:
In-patient segment dominated the global market in 2017. This can be attributed to the rising incidence of chronic diseases, such as cancer, diabetes and autoimmune disorders. According to a study published by NCBI in 2018, it is estimated that around 60 million people are suffering from chronic diseases across the globe. Thus, increasing number of patients with various health conditions is expected to contribute towards revenue growth during forecast years for this application segment.
The out-patient segment is anticipated to witness lucrative growth over the forecast period due largely on account of increasing adoption of interleukin 12 receptor products for treatment purposes outside hospitals and clinics. For instance, according to an article published by The Journal Of Allergy And Clinical Immunology In March 2019, it was reported that around 20% patients have allergic reactions after receiving infusions containing IL-12 antibodies at clinical trials conducted so far. However; these allergic reactions can be treated successfully with antihistamines or epinephrine injection (adrenaline).
Regional Analysis:
North America dominated the global market in 2017. The region is expected to maintain its position during the forecast period. This can be attributed to increasing cases of chronic diseases, rising healthcare expenditure, and high adoption of interleukin 12 inhibitors in clinical trials. In addition, favorable reimbursement policies for novel therapies are also contributing toward growth in this region. For instance, under the Affordable Care Act (ACA), patients with commercially insured plans may access an array of coverage options including off-label uses for approved medicines as well as investigational products such as interleukin 12 inhibitors (IL-12s).
Asia Pacific is anticipated to witness lucrative growth over the forecast period owing to factors such as improving healthcare infrastructure and growing patient awareness regarding treatment options leading towards better diagnosis.
Growth Factors:
- Increasing incidence of autoimmune diseases: The increasing incidence of autoimmune diseases is one of the key growth drivers for the Interleukin 12 receptor market. Autoimmune diseases are caused due to the abnormal functioning of the immune system, which leads to inflammation and damage to tissues and organs. The global prevalence of autoimmune diseases is estimated to be around 235 million, and it is expected to increase further in the coming years. This will create a high demand for Interleukin 12 receptor products and drive the growth of this market.
- Rising awareness about Interleukin 12 receptor therapies: There is a growing awareness among people about Interleukin 12 receptor therapies and their benefits over traditional treatments options such as steroids or immunosuppressants. This is driving patients towards seeking treatment withInterleukin 12 receptorsubstances, thereby propellingthe growthof thismarket segment .
Scope Of The Report
Report Attributes
Report Details
Report Title
Interleukin 12 Receptor Market Research Report
By Type
Edodekin Alfa SR, M-9241, LY-3232094, NMIL-121, Others
By Application
In-Patient, Out-Patient
By Companies
Eli Lilly and Company, Mallinckrodt Plc, Merck KGaA, Neumedicines Inc
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
245
Number of Tables & Figures
172
Customization Available
Yes, the report can be customized as per your need.
Global Interleukin 12 Receptor Market Report Segments:
The global Interleukin 12 Receptor market is segmented on the basis of:
Types
Edodekin Alfa SR, M-9241, LY-3232094, NMIL-121, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
In-Patient, Out-Patient
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Eli Lilly and Company
- Mallinckrodt Plc
- Merck KGaA
- Neumedicines Inc
Highlights of The Interleukin 12 Receptor Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Edodekin Alfa SR
- M-9241
- LY-3232094
- NMIL-121
- Others
- By Application:
- In-Patient
- Out-Patient
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Interleukin 12 Receptor Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Interleukin 12 receptor is a protein that binds to interleukin 12. This interaction allows the immune system to respond to infection or other inflammatory conditions.
Some of the major companies in the interleukin 12 receptor market are Eli Lilly and Company, Mallinckrodt Plc, Merck KGaA, Neumedicines Inc.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Interleukin 12 Receptor Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Interleukin 12 Receptor Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Interleukin 12 Receptor Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Interleukin 12 Receptor Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Interleukin 12 Receptor Market Size & Forecast, 2020-2028
4.5.1 Interleukin 12 Receptor Market Size and Y-o-Y Growth
4.5.2 Interleukin 12 Receptor Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Edodekin Alfa SR
5.2.2 M-9241
5.2.3 LY-3232094
5.2.4 NMIL-121
5.2.5 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 In-Patient
6.2.2 Out-Patient
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Interleukin 12 Receptor Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Interleukin 12 Receptor Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Edodekin Alfa SR
9.6.2 M-9241
9.6.3 LY-3232094
9.6.4 NMIL-121
9.6.5 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 In-Patient
9.10.2 Out-Patient
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Edodekin Alfa SR
10.6.2 M-9241
10.6.3 LY-3232094
10.6.4 NMIL-121
10.6.5 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 In-Patient
10.10.2 Out-Patient
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Edodekin Alfa SR
11.6.2 M-9241
11.6.3 LY-3232094
11.6.4 NMIL-121
11.6.5 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 In-Patient
11.10.2 Out-Patient
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Edodekin Alfa SR
12.6.2 M-9241
12.6.3 LY-3232094
12.6.4 NMIL-121
12.6.5 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 In-Patient
12.10.2 Out-Patient
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Edodekin Alfa SR
13.6.2 M-9241
13.6.3 LY-3232094
13.6.4 NMIL-121
13.6.5 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 In-Patient
13.10.2 Out-Patient
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Interleukin 12 Receptor Market: Competitive Dashboard
14.2 Global Interleukin 12 Receptor Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Eli Lilly and Company
14.3.2 Mallinckrodt Plc
14.3.3 Merck KGaA
14.3.4 Neumedicines Inc
